CClinicalTrials.gg
CompletedNCT03202290BANCOUpdated Jan 22, 2026

BANCO Study: Behavioral Addictions and Related NeuroCOgnitive Aspects: A Monocentric, Prospective, Controlled, Open-label Study of a Sample of Patients With Gambling Disorder

An interventional study of Cognitive and clinical assessment in Gambling Disorder, sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The prevalence of people suffering from gambling disorder is relatively high, and the impact on this disorder the individual and those around him is considerable. The etiopathogenic model of gambling disorder is multifactorial, involving various risk and vulnerability factors, involved in the initiation and maintenance of the disorder. Among these factors, neurocognitive alterations associated with the disorder has recently aroused interest among researchers. In this study, the investigators propose to explore the neurocognitive impairments of patients suffering from gambling disorder compared to a control group, in order to identify alterations that could be the target of cognitive remediation programs. Gambling disorder provides a unique opportunity to study the specific neurocognitive impairments of the addictive process because it is not biased by the neurotoxic effect of substances as it is the case in substance use disorders.

02

Conditions studied

  • Gambling Disorder

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • For the patients :

Aged of more than 18, Suffering from gambling disorder(diagnosis according to DSM-5), Patient starting care in the Addictology and Psychiatry department of the Nantes University Hospital, Mastering the French language, Social Security Affiliates, Having given consent

  • For the volunteers:

Aged of more than 18, Subject not suffering from gambling disorder, Mastering the French language, Social Security Affiliates Having given consent

Exclusion criteria

Exclusion Criteria:

  • For patients :

Having psychiatric and addictive disorders (present and not stabilized mood disorders, anxiety disorders and substance-use disorders except nicotine, lifetime psychotic syndrome, diagnosed by the MINI and after consultation with the clinician), Unstable endocrine disruptions or neurological disorders (such as head trauma, neurodegenerative diseases, unbalanced epilepsy, mental retardation, etc.), Taking a non-stabilized psychotropic treatment for at least 2 weeks Consumption of a psychoactive substance - other than nicotine - within the 12 hours preceding the assessment, Presenting a score on the HAD questionnaire ≥ 11, Having benefited from a current or past RC program, Reporting to be pregnant or nursing, Current participation or in the past month in a pharmacological research protocol, Presenting difficulties for the reading or writing of the French language, Being under guardianship, Presenting disorders of higher functions

  • For volunteers:

Suffering from past or current pathological gambling (DSM-5 diagnosis), Having psychiatric and addictive disorders (mood disorders, anxiety disorders and disorders linked to the use of non-nicotine substance present and not stabilized, life-long psychotic syndrome, diagnosed by the MINI), endocrine or neurological disorders (Cranial trauma, neurodegenerative diseases, unbalanced epilepsy, mental retardation, etc.), Taking a non-stabilized psychotropic treatment for at least 2 weeks, Declaring to have consumed a psychoactive substance - other than nicotine - within the 12 hours preceding the assessment, Presenting a score on the HAD questionnaire ≥ 11, Having benefited from an assumption in current or past RC program, Reporting to be pregnant or nursing, Currently participating or in the past month to a pharmacological research protocol, Presenting difficulties for the reading or writing of the French language, Being under guardianship, Presenting disorders of cognitive functions

04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Other
    Gambling disorder

    patients suffering from gambling disorder

    Behavioral: Cognitive and clinical assessment

  • Other
    Controls

    healthy controls

    Behavioral: Cognitive and clinical assessment

Interventions

  • BehavioralCognitive and clinical assessment

    The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)

05

What researchers measure

Primary outcomes

  1. Mean difference of the scores obtained at the various neurocognitive tests between the group of disordered gamblers and the group of healthy controls

    Time frame: 2.5 hours

06

Study locations

1 site
  • CHU de Nantes
    Nantes, 44093, France
07

References and documents

Publications

  • Hurel E, Grall-Bronnec M, Thiabaud E, Saillard A, Hardouin JB, Challet-Bouju G. A Case-Control Study on Behavioral Addictions and Neurocognition: Description of the BANCO and BANCO2 Protocols. Neuropsychiatr Dis Treat. 2021 Jul 20;17:2369-2386. doi: 10.2147/NDT.S292490. eCollection 2021. PubMed 34321880 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03202290
Lead sponsor
Nantes University Hospital
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Aug 24, 2018
Primary completion
Jan 8, 2026
Completion
Jan 8, 2026
Last update
Jan 22, 2026

Study contacts

Marie GRALL BRONNEC, Pr
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion